Evidence map›Paper›PMID 35095921›Full record

ArticleFrontiers in immunology2021

Use of a

Gillian A Lang, Kaylee Norman, Souwelimatou Amadou Amani, Tyler M Shadid, Jimmy D Ballard, Mark L Lang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The immune system in neurological diseases: What innate-like T cells have to say.The Journal of allergy and clinical immunology · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gillian A LangDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Kaylee NormanDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Souwelimatou Amadou AmaniDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Tyler M ShadidDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Jimmy D BallardDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Mark L LangDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
University of Oklahoma Health Sciences Center · US

Funding

Differential Effects of TcdB1 and TcdB2 in C. difficile diseaseR01AI119048 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BALLARD, JIMMY D. · 2015 to 2024
$3.8M
Activation of semi-invariant and diverse NKT cells with an adjuvant combinationR01AI134719 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI LANG, MARK L · 2018 to 2022
$1.8M
NIAID NIH HHS R01 AI119048NIAID NIH HHS R01 AI134719
6 · The paper itself

Abstract

Adjuvant combinations may enhance or broaden the expression of immune responses to vaccine antigens. Information on whether established Alum type adjuvants can be combined with experimental CD1d ligand adjuvants is currently lacking. In this study, we used a murine

Indexed as

Adjuvants, VaccineAlum CompoundsAnimalsBacterial VaccinesBiomarkersClostridioides difficileClostridium InfectionsDisease Models, AnimalDose-Response Relationship, ImmunologicFemaleImmunizationImmunophenotypingLigandsLymphocyte ActivationMiceNatural Killer T-CellsAdjuvants, VaccineAlum Compoundsaluminum sulfateBacterial VaccinesBiomarkersLigandsadjuvantAlhydrogel™AlumCD1dimmunizationα-galactosylceramide

Identifiers

PMID35095921
PMCPMC8794951
OpenAlexW4206097009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.